We examined the effect of p38 mitogen-activated protein kinase (MAPK) inhibitors in models of nociception and correlated this effect with localization and expression levels of p38 MAPK in spinal cord. There was a rapid increase in phosphorylated p38 MAPK in spinal cord following intrathecal administration of substance P or intradermal injection of formalin. Immuncytochemisty revealed that phosphorylated p38 MAPK-immunoreactive cells were predominantly present in laminae I-IV of the dorsal horn. Double-staining with markers for neurons, microglia, astrocytes and oligodendrocytes unexpectedly revealed co-localization with microglia but not with neurons or other glia. Pretreatment with p38 MAPK inhibitors (SB20358 or SD-282) had no effect on acute thermal thresholds. However, they attenuated hyperalgesia in several nociceptive models associated with spinal sensitization including direct spinal activation (intrathecal substance P) and peripheral tissue inflammation (intraplantar formalin or carrageenan). Spinal sensitization, manifested by enhanced expression of cyclo-oxygenase-2 and inflammation-induced appearance of Fos-positive neurons, was blocked by pretreatment, but not post-treatment, with p38 MAPK inhibitors. Taken together, these results indicate that spinal p38 MAPK is involved in inflammation-induced pain and that activated spinal microglia play a direct role in spinal nociceptive processing.
Chronic pain states subsequent to tissue injury and inflammation in humans and animals are hallmarked by increased sensitivity to subsequent stimulation. This hyperalgesia arises in large part from facilitated processing of noxious input at the spinal level (Dickenson et al. 1997) . Studies have shown that this spinal facilitation is mediated by a complex biochemical cascade initiated by the activation of high-threshold primary afferent C-fibers. Acute activation of NMDA and neurokinin-1 (NK-1) receptors by glutamate and substance P (sP) released from the primary afferents results in increased intracellular calcium concentrations in dorsal horn neurons, downstream activation of phospholipase A 2 (PLA 2 ) (Lazarewicz et al. 1990 ; Kim et al. 1995) and generation of prostaglandins through the action of constitutively expressed spinal cyclooxygenase (COX-2) (Chen et al. 1997) . Prostaglandins, acting through specific receptors, depolarize dorsal horn neurons (Baba et al. 2001) and enhance primary afferent transmitter release (Nicol et al. 1992) . The relevance of this cascade to pain processing has been confirmed by the observation that inhibition of spinal NMDA or NK-1 receptors, or either PLA 2 or COX-2 activity, reliably attenuates injury and inflammation-induced hyperalgesia (Svensson and Yaksh 2002) .
Mitogen-activated protein kinases (MAPKs) are serinethreonine kinases that play an instrumental role in signal transduction from the cell surface to the nucleus. p38 MAPK represents a group of enzymes in the MAPK family that are phosphorylated and activated by a variety of physical and chemical stimuli (Obata et al. 2000) . Once activated, p38 MAPK phosphorylates nuclear and cytosolic targets to regulate responses, such as cell differentiation, apoptosis and inflammation-induced cytokine production (Shi and Gaestel 2002) .
Several lines of evidence suggest that p38 MAPK is activated by factors that are involved in pain signaling. In the dorsal root ganglion of primary sensory neurons peripheral inflammation and nerve injury induces p38 MAPK activation and the corresponding nociceptive behaviors are prevented by p38 MAPK inhibition (Ji et al. 2002; Schafers et al. 2003) . Peripheral inflammation and nerve injury also activates p38 MAPK in spinal cord. It has been reported that injection of formalin into the paw and peripheral nerve axotomy induces p38 MAPK activation in microglia (Kim et al. 2002) . However, at present it is unclear whether activation of spinal p38 MAPK contributes to nociceptive processing. A number of in vitro studies suggests that p38 MAPK participates in signaling pathways that mediate nociception at the spinal site. Glutamate signaling through the NMDA receptor induces phosphorylation of p38 MAPK in primary neuronal cultures (Kawasaki et al. 1997; Chen et al. 2003) . Phosphorylated p38 (P-p38) MAPK appears in astrocytes after sP stimulation (Fiebich et al. 2000) and p38 MAPK-mediated phosphorylation enhances PLA 2 activity (Lin et al. 1993; Borsch-Haubold et al. 1997; Hiller and Sundler 1999; Zhu et al. 2001) in immune cells and platelets.
In the present studies, we demonstrate that direct activation of NK-1 receptors and peripheral inflammation trigger phosphorylation of spinal p38 MAPK, and we show, by selective inhibition of spinal p38 MAPK, that this kinase is pivotal in facilitation of nociceptive signaling at the spinal level. Unexpectedly, we also found that activated spinal p38 MAPK is primarily present in spinal microglia, suggesting a critical role for this non-neuronal cell type in spinal pain processing.
Materials and methods

Animals
All experiments were carried out according to protocols approved by the Institutional Animal Care Committee of University of California, San Diego. Male Sprague-Dawley rats (300-350 g) were housed individually in micro-isolator filter cages and maintained on a 12-h light-dark cycle with free access to food and water.
Chronic lumbar intrathecal catheters were implanted under isoflurane anesthesia according to a modification of the procedure described by Yaksh and Rudy (1976) . Briefly, a polyethylene catheter (PE-10) was inserted through an incision in the atlantooccipital membrane and advanced caudally to the rostral edge of the lumbar enlargement. Studies involving rats with chronic intrathecal catheters were carried out 5-8 days after implantation, and all agents were injected in 10 lL followed by 10 lL saline to flush the catheter. Rats were monitored daily for signs of neural dysfunction and were removed from the study if neurological dysfunction was noted, if there was greater than 10% weight loss over 5 days or if the catheter was occluded. Less than 5% of the animals were excluded.
Intrathecal drugs
Sp (Sigma, St Louis, MO, USA) was dissolved in physiological saline, and SD-282 (Scios Inc. Sunnyvale, CA, USA) and SB203580 (SB) Calbiochem-Novabiochem International; San Diego, CA, USA) were dissolved in 5% dimethylsulfoxide and 5% Cremophor EL (Sigma) in saline. Intrathecal injection of vehicle (5% dimethylsulfoxide and 5% Cremophor EL in physiological saline) had no effect on nociceptive thresholds/behavior or protein expression/phosphorylation.
Nociceptive models
To directly induce spinal sensitization, rats received intrathecal injections of sP (30 nmol), which activates spinal NK-1 receptors and produces thermal hyperalgesia (Piercey et al. 1981; Yashpal and Henry 1983) . To induce a state of local peripheral inflammation, carrageenan (100 lL, 2% in physiological saline; Sigma) was injected subcutaneously into the plantar surface of the left hind paw under light isoflurane anesthesia. Thermally-evoked paw withdrawal responses were assessed using a Hargreaves-type testing device (Yaksh et al. 2001b) . Briefly, rats were placed on a glass surface maintained at 30°C. The thermal nociceptive stimulus originates from a projection bulb below the glass surface, and the stimulus is delivered separately to one hind paw at a time. The animals were allowed to acclimatize on the glass surface and basal paw withdrawal latencies (PWLs) were then assessed for left and right paws at time (t) ¼ ) 40, )30 and )20 min, and expressed as the mean of the six measurements (sP study) or the mean for each paw (carrageenan study). At t ¼ ) 10 min the animals received intrathecal vehicle or drug, and at t ¼ 0 sP or carrageenan was injected. PWLs were then assessed at t ¼ 10, 20, 30, 45 and 60 min for the sP group, and at t ¼ 30, 60, 90,120, 150, 180 and 240 min for the carrageenan group. The PWL for each group was expressed as the mean at each time point and as the hyperalgesic index. The hyperalgesic index is a calculation that defines the magnitude of sP-or carrageenan-induced sensitization. It represents the area under the time-effect curve after stimulation, in which the percentage reduction from baseline (e.g. pre-carrageenan) response latency is plotted against time. The resulting metric is percentage change · time (minutes). The formula for calculating the percentage change is: (baseline latency ) post-drug latency) · 100/(baseline latency) where latency is expressed in seconds. Increasing values show increasing hyperalgesia.
To quantify formalin-induced flinching, an automated sensing system was employed (Yaksh et al. 2001b) . Briefly, a soft metal band (10 mm wide and 27 mm long, shaped into a C, and weighing 0.5 g) was placed on the hind paw of the animal being tested. Animals were allowed to acclimatize in individual Plexiglas chambers for 30 min before being moved to a test chamber. Just before the animals were placed into the test chamber, they were briefly restrained in a cloth towel, and 5% formalin (in 50 lL physiological saline) was injected into the dorsal side of the banded paw. Data collection was initiated after the animal had been placed inside the test chamber. Nociceptive behavior was quantified by automatically counting the incidence of spontaneous flinching or shaking of the injected paw. The flinches were counted for 1-min periods for 60 min; the flinch data are expressed as number of flinches per min and total flinches observed during phase 1 (0-9 min) and phase 2 (10-60 min).
Western blot
Rats were deeply anesthetized then decapitated, and the spinal cords were ejected from the vertebral column by means of a saline-filled syringe. The lumbar part of the spinal cord was immediately homogenized in extraction buffer (50 mM Tris buffer, pH 8.0, containing 0.5% Triton X-100, 150 mM NaCl, 1 mM EDTA, phosphatase and protease inhibitors) by sonication. The tissue extracts were subjected to denaturing Nu Ò PAGE 4-12%
Bis-Tris gel electrophoresis and then electrophoretically transferred to nitrocellulose membranes (Micronic Separation Inc. Westborough, MA, USA). After blocking non-specific binding sites with 5% low-fat milk in phosphate-buffered saline (PBS) containing 0.1% Tween 20 for 1 h in room temperature, the membranes were probed with antibodies overnight at 4°C. After washing, the antibody-protein complexes were probed with appropriate secondary antibodies labeled with horseradish peroxidase for 1 h at room temperature, and detected with chemiluminescent reagents. The nitrocellulose membranes were stripped with Re-Blot western blot recycling kit (Chemicon, Temecula, CA, USA) and reblotted with different antibodies. The antibodies used detect P-p38 MAPK (1 : 500), total p38 MAPK (1 : 500) (Cell Signaling Technology, Beverly, MA, USA), COX-1 (1 : 500) and COX-2 (1 : 1000) (Cayman Chemical, Ann Arbor, MI, USA). The intensity of immunoreactive bands was quantified using ImageQuant software (Molecular Dynamics, Sunnyvale, CA, USA). P-p38 MAPK bands were normalized relative to the total p38 MAPK, and COX-2 bands relative to COX-1, in each sample. The results from each treatment on each western blot are expressed as the percentage change from baseline (control), where the control is the mean result from three spinal cords of animals that received vehicle. For calculations, the control data represent the mean and SEM of each control observation divided by the grand mean of all control observations for that blot.
Immunohistochemistry
After intrathecal injection of sP or vehicle, the animals were deeply anesthetized with sodium pentobarbital (50 mg/kg bodyweight) and perfused intracardially with heparinized saline (200 mL) followed by freshly prepared 4% paraformaldehyde in 0.1 M PBS, pH 7.4 (Sigma). The lumbar spinal cord was removed, post-fixed in the same fixative for 6 h, and transferred to PBS containing 20% sucrose for 72 h. The lumbar segments L3-6 were dissected, and transverse sections (10 lm) were cut with a freezing microtome and mounted on silane-covered glass slides. Sections from vehicle-treated and sPtreated animals, mounted side by side, were incubated in polyclonal rabbit-P-p38-antiserum (1 : 100 dilution with 0.5% Triton X-100 and 5% goat serum in PBS; Cell Signaling Technology) overnight at 4°C under gentle agitation. Binding sites were visualized with anti-rabbit IgG antibodies conjugated with Alexa-488 (1 : 5000 dilution with 0.5% Triton X-100 and 5% goat serum in PBS; Molecular Probes, Eugene, OR, USA). To determine the cellular distribution of P-p38 MAPK, neurons, astrocytes, microglia and oligodendrocytes were counterstained with primary antibodies raised in mouse against Neuronal N (Neu N) (1 : 1000; Chemicon, Temecula, CA, USA), glial fibrillary acid protein (GFAP) (1 : 500; Chemicon), CD11b (OX-42) (1 : 100; Biosource International, Camarillo, CA, USA) and APC (1 : 500, Oncogene Research Products, San Diego, CA, USA) respectively. Binding sites were visualized with anti-mouse IgG antibody conjugated with Alexa-594 (1 : 5000 with 0.5% Triton X-100, 5% and goat serum in PBS; Molecular Probes). The sections were also stained with 4¢,6¢-diamidino-2-phenylindole hydrochloride (DAPI) (1 : 5000), a general nuclear marker. Coverslips were mounted on the glass slides with ProLong anti-fade medium (Molecular Probes). Non-specific staining was determined by excluding the primary antibodies. Images were captured using a fluorescence microscope (Olympus, Melville, NY, USA) and a DeltaVision deconvolution microscopic system operated by SoftWorx software (Applied Precision, Issaquah, WA, USA). Optical sections through the samples were taken at increments of 0.2 lm. The images were deconvolved and examined either section by section or as volume views generated by combining areas of maximal intensity of each optical section with SoftWorx programs. Rats that underwent intrathecal administration of SD-282 or vehicle followed by formalin injection into the paw were anesthetized and perfused according to the method described above. The lumbar part of the spinal cord was cryocut in serial sections (20 lm). Endogenous peroxidase activity was blocked by free-floating incubation in 0.3% H 2 O 2 for 30 min and non-specific binding sites were blocked in 0.5% Triton X-100 and 5% goat serum in PBS for 4 h, followed by incubation with polyclonal rabbit antibody against Fos protein (1 : 10 000; Calbiochem-Novabiochem Corporation) for 72 h in 4°C. The binding sites were visualized using ABC kit (Vector Laboratories, Burlingame, CA, USA). The signal was developed in diaminobenzidine-tetrahydrochloride solution containing H 2 O 2 in PBS. When a light background appeared, the reaction was stopped by four washes with PBS. Non-specific staining was determined by excluding the primary antibody. Sections were washed in distilled water, mounted on slides, air-dried, dehydrated through graded ethanol solutions followed by xylene, and then coverslipped. For each group a minimum of 10 sections (nine sections apart, at spinal segment 3-6 level) was analyzed, and the number of Fos-positive neurons were counted in the ipsilateral and contralateral dorsal quadrants.
Statistical analysis
Six to eight rats were included in each group for the intrathecal sP, formalin, carrageenan and thermal inflammation hyperalgesia measurements, and four to six animals per group for the quantitative assessment of Fos-positive neurons (10 sections per animal at least nine consecutive sections apart). For assessment of protein levels by western blotting, six animals were included in each group. Values are expressed as mean ± SEM. Differences between groups were compared with one-way ANOVA and Tukey post-hoc test using Prism statistical software (San Diego, CA, USA).
Results
Intrathecal sP activates spinal p38 MAPK and induces thermal hyperalgesia Western blots of spinal cord protein extracts revealed that p38 MAPK is constitutively expressed in control, nonstimulated, animals (Fig. 1a) . As noted, p38 MAPK is active in its phosphorylated state, a form that we found to be present constitutively at low levels in lumbar dorsal horn tissue after intrathecal injection of saline (Fig. 1a) . However, a fourfold increase in P-p38 MAPK was detected in spinal cord homogenates 10 min after intrathecal administration of sP (30 nmol) (Figs 1a and b). In tandem with p38 MAPK activity, intrathecal administration of sP (30 nmol) also resulted in a potent thermal hyperalgesia (Fig. 1c) . The PWL dropped precipitously from a baseline level of 12.2 ± 0.5 to 7.8 ± 0.6 s 15 min after intrathecal administration of sP. Previous work has shown that this hyperalgesia is reversed by spinal delivery of NK-1 receptor antagonists .
p38 MAPK inhibition prevents hyperalgesia
To determine the role of spinal p38 MAPK activation in nociceptive behavior, we examined the ability of SB, a moderately selective p38 MAPK inhibitor and SD-282, a recently developed highly selective p38 MAPK inhibitor, to antagonize thermal hyperalgesia evoked by intrathecal injection of sP. Both intrathecal SB (30 lg) and SD-282 (60 lg) completely blocked sP-induced thermal hyperalgesia (Fig. 1c) .
Peripheral inflammation induces activation of spinal p38 MAPK and the hyperalgesia is suppressed by inhibition of spinal p38 MAPK Injection of formalin into the paw evokes an initial burst of C-fiber afferent input followed by a persistent low level discharge (Puig and Sorkin 1996) . This results in a biphasic increase in the activity of dorsal horn wide dynamic range neurons (Haley et al. 1990) , and a parallel biphasic appearance of paw flinching, in which phase 2 represents spinal sensitization (Yaksh et al. 2001b) . Intrathecally administered NK-1 inhibitors diminish formalininduced hyperalgesia (Haley et al. 1990) . As inhibition of p38 MAPK blocks NK-1-mediated hyperalgesia, it is possible that spinal p38 MAPK is involved in inflammation-induced spinal sensitization. Measurement of P-p38 MAPK showed that in normal non-stimulated spinal cord, P-p38 MAPK levels were low. However, 5 min after formalin injection into the plantar surface of the right hind paw, a twofold increase in P-p38 MAPK immunoreactivity was detected in homogenates of lumbar ipsilateral dorsal horn by western blotting (Figs 2a and b) . This phosphorylation was transient. By 20 min after formalin injection P-p38 MAPK levels had returned to baseline. The significance of this p38 MAPK activation is indicated by the observation that intrathecal injection of either SD-282 or SB 10 min before paw formalin injection resulted in potent attenuation of the second phase of flinching behavior (Fig. 2c) . In Fig. 2(d) the total number of flinches during phase 2 (10-60 min after formalin injection) is shown. Intrathecal administration of p38 MAPK inhibitors reliably reduced the pain behavior by more than 50%.
When carrageenan is injected into the plantar surface of a paw, a characteristic inflammation and associated thermal hyperalgesia are produced. The mean baseline PWL was 11.3 ± 0.8 s before carrageenan injection. Two hours after carrageenan injection into the paw a highly significant reduction in PWL to 3.9 ± 0.2 s was observed in vehiclepretreated animals, and this hyperalgesia lasted throughout the study (Fig. 3a) . Intrathecal pretreatment with either SD-282 or SB resulted in a blockade in the onset of carrageenan-induced thermal hyperalgesia (Fig. 3a) . The hyperalgesic index was calculated for each drug and dose over the time period 0-240 min. Pretreatment with either MAPK inhibitor produced a statistically significant dose- dependent antihyperalgesia (Fig. 3b) . Importantly, this effect was observed only on the inflamed paw. There were no changes, even after the highest dose of either compound, in the response latency of the uninflamed paw (p > 0.5; data not shown). Thus, the effect of the p38 MAPK inhibitors is antihyperalgesic rather than analgesic.
Activated p38 MAPK is localized in spinal microglia
The potent and pervasive effects of p38 MAPK inhibition observed in these studies led us to investigate the cellular locus of spinal p38 MAPK. Frozen transverse spinal cord sections taken from L3-L6 segments were prepared and immunostained with antibodies against P-p38 MAPK, microglia (OX-42), neurons (NeuN), astrocytes (GFAP) or oligodendrocytes (APC). In comparison to control salineinjected animals, significantly more P-p38 MAPK-positive cells were detected after intrathecal sP (Figa 4a and b). P-p38 MAPK positive cells were localized predominantly in laminae I-IV (Figs 4a-d) . Figs 5a and c) , astrocytes or oligodendrocytes (Figs 6a and b) . Microglia also displayed morphological signs of activation after intrathecal administration of sP. Although not quantified systematically, examination indicated a consistent increase in the size of cell bodies and processes. In these microglia, varicosity-like profiles were observed in proximity to the limiting membrane of NeuN-positive cells, indicating probable communication between activated microglia and neurons. No immunopositivity was detected when the primary antibodies were excluded (data not shown).
Confocal analysis revealed that P-p38 MAPK co-localized with microglia (Figs 5b and d). No P-p38 MAPK expression was detected in neurons (
p38 MAPK inhibition prevents spinal Fos and COX-2 expression induced by intradermal formalin and intrathecal sP
To determine whether spinal p38 MAPK is involved in regulation of transcription factors and protein expression associated with nociceptive stimulation, we examined the effects of p38 MAPK inhibition on activation of spinal c-fos, an immediate early gene reflective of neuronal activation, and up-regulation of COX-2, an enzyme important to injuryinduced spinal facilitation of nociceptive input. In the control group, which received intrathecal vehicle but no paw formalin, 4.4 ± 1.7 Fos-positive neurons were counted per section of the dorsal horn. Two hours after injection of formalin into the paw (Figs 7a,b and e) (Herdegen et al. 1994; Yang et al. 1997) there was a pronounced increase in the number of Fos-immunoreactive neurons (49.4 ± 5.8) in ipsilateral lamina I-VI in spinal segments level 3-6. Intrathecal injection of the selective p38 MAPK inhibitor SD-282, 10 min before formalin injection, resulted in a decrease in the number of Fos-positive neurons (18.5 ± 3.5; dorsal horn, ipsilateral side) (Figs 7c and e) . No immunopositivity was detected when the primary antibody was excluded (Fig. 7d) .
Four hours after intrathecal injection of intrathecal sP, the level of COX-2 protein increased (70 ± 27%) in the dorsal horn (Figs 8a and b) . Prior inhibition of spinal p38 MAPK with intrathecal SD-282, at a dose that blocked thermal hyperalgesia (Fig. 1c) , prevented the subsequent up-regula- Fig. 5 Confocal images depicting co-localization of P-p38 MAPK and microglia-like structures, but not neuronal structures, in spinal dorsal horn 10 min after intrathecal injection of sP. Sections were doublelabeled with anti-P-p38 MAPK (green; a-d) and NeuN (red; a, c), an antibody that recognizes neuronal cell bodies, and OX-42 (red; b, d), an antibody recognizes microglia. Sections were also stained with DAPI (blue), a general nuclear marker. No co-localization was observed between p38 MAPK and NeuN (a, c). OX-42 and P-p38 MAPK labeling showed overlap, indicating that p38 was phosphorylated in microglia after intrathecal injection of sP. Size bars represent 50 lm. Fig. 6 Micrographs showing no co-localization between P-p38 and astrocytes or oligodendrocytes. Sections were double-labeled with anti-P-p38 MAPK (green; a, b) and the astrocyte marker GFAP (red; a) and oligodendrocyte marker APC (red; b). No co-localization was observed between p38 MAPK and GFAP or APC in the dorsal horn of the lumbar spinal cord 10 min after intrathecal administration of sP. Size bars represent 50 lm.
Spinal pain processing 1539 tion of COX-2 protein following intrathecal sP. No changes in the level of COX-1 were seen after intrathecal injection of sP (Fig. 8a) .
Post-treatment with intrathecal p38 MAPK inhibitor does not prevent hyperalgesia The question of whether p38 MAPK contributed to the induction or maintenance of spinal sensitization led us to consider whether p38 MAPK inhibition would be equally effective when administered before or after the nociceptive stimulus. Accordingly, we examined the effects of intrathecal SD-282 when the inhibitor was given 5 min after paw formalin injection. In contrast to pretreatment, post-treatment did not result in a reduction in pain behavior (Fig. 2d) nor did it prevent the intrathecal sP-evoked increase in spinal COX-2 protein expression (Figs 8a and b) .
Discussion
Spinally mediated hyperalgesia is a frequent component of the pain experience following tissue injury . It is widely believed that this spinal sensitization reflects a cascade of events that is initiated in part by persistent sensory input generated by tissue injury and inflammation, and the subsequent spinal primary afferent release of excitatory amino acids (glutamate) and peptides (Sp). The present study makes three essential points in support of the hypothesis that activation of spinal p38 MAPK in populations of microglia plays a pivotal role in downstream events that are initiated by tissue inflammation and lead to behaviorally defined hyperalgesia.
First, we show that p38 MAPK is constitutively expressed in spinal cord and that spinal p38 MAPK is activated following peripheral and spinal stimulation. There is a low but detectable level of P-p38 MAPK in spinal cord following injection of vehicle and decapitation under deep anesthesia. It has been reported that p38 MAPK in dorsal root ganglion neurons is activated following peripheral inflammation (Ji et al. 2002) . In order to focus our work on the potential role of p38 MAPK in spinal cord, afferent input was mimicked by intrathecal injection of sP, which allows direct activation of spinal NK-1 receptors, bypassing the peripheral tissue. A robust increase in immunopositive signal for P-p38 MAPK was observed after administration of sP, indicating that spinal p38 MAPK is phosphorylated as a result of synaptic activity. Injection of formalin into the paw, known to cause hyperalgesia in a sP-dependent fashion (Yamamoto and Yaksh 1991) , elicited a similar activation of spinal p38 MAPK. It has previously been reported that there is no change in the levels of P-p38 MAPK in parallel with inflammation-induced hyperalgesia (Ji et al. 2002) . It is possible that p38 MAPK activation is very rapid and transient, triggering downstream events that are maintaining pathological hyperalgesia. This might explain why no increase in phosphorylation was observed in spinal cords examined at later time points. A transient role for p38 MAPK in inflammation-induced hyperalgesia is supported by the observation that injection into the paw induced phosphorylation of p38 MAPK that peaked at about 5 min. This in vivo phosphorylation of p38 MAPK parallels in vitro work, in which stimulation of NK-1 and NMDA receptors was shown to result in p38 MAPK phosphorylation (Kawasaki et al. 1997; Fiebich et al. 2000) .
Second, the acute hyperalgesia in diverse behavioral models was prevented, in a dose-dependent fashion, by intrathecal pre-administration of two p38 MAPK inhibitors, SB and SD-282. Although SB is widely used as a p38 MAPK inhibitor, interpretation of its actions are confounded by its COX inhibitory properties (Borsch-Haubold et al. 1998) . In contrast, SD-282 is selective for p38 MAPK. The inhibitors do not block phosphorylation of p38 MAPK but prevent p38 MAPK from phosphorylating its substrates. Importantly, the potent antihyperalgesia exhibited by p38 MAPK inhibitors delivered intrathecally before intrathecal sP emphasizes that the reduction in formalin-and carrageenaninduced hyperalgesia was probably not secondary to a peripheral anti-inflammatory action. Accordingly, these observations provide strong support for a spinal role played by p38 MAPK in pain processing.
Third, the basal P-p38 MAPK protein seen in western blots of spinal cord homogenates was found only in cells positive for OX-42, a marker for microglia. More importantly, after direct activation of spinal NK-1 receptors leading to an increase in P-p38 MAPK protein, histochemistry revealed that this enhanced P-p38 MAPK immunoreactivity was present predominantly in OX-42-positive cells and that these cells typically displayed the plump morphological profiles characteristic of activated microglia. The present effects of intrathecal sP are in accord with in vitro work showing sP-induced activation of microglia in culture (Laurenzi et al. 2001; Rasley et al. 2002) . Both peripheral inflammation and nerve injury activate glial cells in the spinal dorsal horn, and a role for glial cells in altering neural excitability has been hypothesized (Sweitzer et al. 1999; Watkins et al. 2001) . Our findings of activated p38 MAPK primarily in spinal microglia after nociceptive stimulation, and the potent actions of spinal p38 MAPK inhibitors, support this hypothesis. Although glia have typically been thought to have a supportive role in neuronal function, these cells also express receptors for many neurotransmitters and neuromodulators (Inagaki et al. 1991; Palma et al. 1997; Kommers et al. 1998) . Glia also synthesize and release neuroactive factors upon activation, including prostanoids and cytokines (Watkins and Maier 2000) . The activation of p38 MAPK seen in this study might represent a direct effect of sP released from the afferent terminal binding to NK-1 receptors present on microglia (Rasley et al. 2002) . It is also possible that the activation of p38 MAPK in microglia is an indirect effect of NK-1 receptor activation, mediated by factors released from neurons upon stimulation. For example, it has been shown that the chemokine fractalkine is cleaved off neuronal membranes following exposure to excitatory concentrations of glutamate (Chapman et al. 2000) . The fractalkine receptor CX3CR1 is predominantly found on microglia (Harrison et al. 1998) . We believe that communication between neurons and microglia through fractalkine-CX3CR1 receptor interaction may regulate microglial involvement in nociceptive processing and accordingly initiate activation of microglial p38 MAPK. Intriguingly, p38 MAPK is activated in monocytes in response to fractalkine exposure (Cambien et al. 2001) .
The MAPK family has several members, including the extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and p38 MAPK, and they are activated through different upstream transduction chains. It has been shown that the ERK isoforms (ERK1/2) are phosphorylated in spinal cord neurons after peripheral inflammation (Ji et al. 1999) and in astrocytes after partial sciatic nerve ligation (Ma and Quirion 2002) . Inhibitory effects on formalin-induced flinching, similar to those observed in the present study using p38 MAPK inhibitors, were seen when an ERK inhibitor was given intrathecally (Ji et al. 1999) . Neither the inhibition of ERK nor p38 MAPK completely abolished flinching, which may reflect submaximal doses or parallel pathways. Given that phosphorylated ERK was detected in neurons, whereas we localized p38 MAPK in microglia, it is possible that both ERK and p38 MAPK pathways contribute to formalininduced pain behavior, but within different cell types.
Spinal p38 MAPK may contribute to spinal sensory processing at several levels. In the scope of this work, most effects of p38 inhibition were observed before changes in protein levels could occur, indicating that p38 MAPK acts on constitutive targets (enzymes, receptors or ion channels). One possible immediate p38 MAPK-mediated effect is phosphorylation of PLA 2 , leading to activation of PLA 2 , arachidonic acid release and prostaglandin E 2 production (BorschHaubold et al. 1997) . Previous work has shown that intrathecal NMDA can evoke prostaglandin E 2 release and a Spinal pain processing 1541 potent hyperalgesia that is reversed by COX-2 (Yaksh et al. 2001a ) and p38 MAPK inhibition .
In addition to acute phosphorylation effects, activation of p38 MAPK mediates transcriptional regulation, either through direct activation of transcription factors or by activation of cytoplasmic targets such as other kinases. Long-term adaptive changes, by increased expression of proteins through activation of transcription factors and stabilization of mRNA (Lasa et al. 2000) , are important for maintaining spinal sensitization. Up-regulation of COX-2 in the spinal cord after peripheral inflammation has been demonstrated and is thought to play an important role in the evolution of the persistent hyperalgesia characteristic of chronic inflammatory states (Samad et al. 2001) . Transcription factors such as CREB and ATF-2 are activated by p38 MAPK and bind to the CRE element in the promoter region of the COX-2 gene, and are likely to be a part of the regulatory machinery for this enzyme (Schroer et al. 2002) . In the present study, we demonstrated that increased spinal expression of COX-2 is prevented by pretreatment with intrathecal p38 MAPK inhibitors. Spinal expression of the immediate early gene product Fos is commonly used as a marker for neuronal activity. Fos expression is markedly enhanced by persistent afferent input as generated by peripheral inflammation and injury (Dubner and Ruda 1992; Dai et al. 2001) . In the present study, spinal induction of Fos by a noxious stimulus (intraplantar formalin) was reduced by pretreatment with p38 MAPK inhibitor, indicating an involvement of p38 MAPK in regulation of long-term changes leading to hyperalgesia.
It is important to note that post-treatment with intrathecal SD-282 did not have an effect on chemically or thermally induced nociception, nor did it prevent up-regulation of sPinduced spinal COX-2. These observations indicate that the relevant actions of p38 MAPK in these models are transient. Once the downstream targets are phosphorylated the cascade of events leading to hyperalgesia is not prevented by spinal p38 MAPK inhibition. Nevertheless, it is possible that there is a pathological increase in phosphorylation of p38 MAPK in more chronic pain states. A promising role for p38 MAPK inhibition as a pharmaceutical tool is highlighted by the results of recent clinical trials with oral p38 MAPK inhibitors that showed antiinflammatory effects during endotoxemia (Branger et al. 2002; Fijen et al. 2002) . Inhibition of p38 MAPK represents a possible solution to the problem of the multiple, parallel neurochemical pathways involved in nociceptive processing. As such, it represents a conceptual advance compared with strategies that interfere with actions such as COX inhibition, which lie downstream of p38 MAPK. These data provide a unique confluence of evidence indicating an important role for p38 MAPK in spinal sensitization and suggest a functional contribution of nonneuronal cells in spinal sensory processing.
